LifeMD Now Offers Eli Lilly's New Oral GLP-1 Foundayo for Weight Management
LFMD sits 33% above its 52-week low of $2.56.
Summary
LifeMD, a virtual primary care provider, announced it is now offering Eli Lilly and Company's newly FDA-approved oral GLP-1 drug, Foundayo (orforglipron), for weight management. This significant expansion integrates Foundayo into LifeMD's weight management program via LillyDirect, providing eligible patients with a convenient oral alternative to injectable GLP-1 therapies. The addition of Foundayo, which has a starting self-pay price of $149 per month, is a material positive for LifeMD, enhancing its competitive position in the rapidly growing GLP-1 market and potentially driving substantial revenue growth. Traders will monitor patient enrollment and the financial impact of this new offering on LifeMD's upcoming results.
At the time of this announcement, LFMD was trading at $3.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.1M. The 52-week trading range was $2.56 to $15.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.